Pretargeted radioimmunotherapy may eliminate colorectal cancer

(Society of Nuclear Medicine) An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging are unveiling a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

This study investigated the impact of immune-related pathway inhibition, among them indolamine 2,3-dioxygenase (IDO), alone and together with immune cells on growth and viability of colorectal cancer (CRC) cells. A panel of patient-derived CRC cell lines with different molecular characteristics (CpG island methylator phenotype, chromosomal, and microsatellite instability) was included. Initial phenotyping of CRC cell lines (n=17) revealed high abundance of immunosuppressive checkpoint-molecules in general, but an individual profile for IDO. Presence of immune-related molecules was independent of the molecular subtype. Sele...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Far too often, cancer patients and their doctors aren ’t aware of all the side effects that accompany new cancer therapies. Some of these new medications might cause fatigue, muscle aches, general pain and discomfort. A lack of information can lead to patients being unprepared to manage their symptoms or even cause some to delay or stop treatment all together. Historically, many clinical trials did not have a method to analyze or widely report the patient’s experience while undergoing a therapy.  Researchers at UCLA and across the country are trying to change that. To help people in making better-informed ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Abstract: Genomic analyses in oncologic care allow for the development of more precise clinical laboratory tests that will be critical for personalized pharmacotherapy. Traditional biopsy-based approaches are limited by the availability of sequential tissue specimens to detect resistance. Blood-based genomic profiling (“liquid biopsy”) is useful for longitudinal monitoring of tumor genomes and can complement biopsies. Tumor-associated mutations can be identified in cell-free tumor DNA (ctDNA) from patient blood samples and used for monitoring disease activity. The US Food and Drug Administration approved a li...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Review Articles: Focus on Pharmacodynamic Drug Monitoring Source Type: research
Authors: Liu S, Dong H, Wu J, Wang C Abstract The histone methyltransferase SET8 is regulated by microRNA-502 through the binding site in its 3'-untranslated region, and the rs16917496 polymorphism at the miR-502-binding site in the SET8 gene has been implicated in a number of cancer types. The rs16917496 polymorphism including CC, CT and TT genotypes was analyzed in patients with colorectal cancer; the CC genotype was identified to be independently associated with longer post-operative survival times using multivariate analysis (relative risk, 2.406; 95% confidence interval, 1.017-5.691; P=0.046). In addition, dec...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Buck E, Sprick M, Gaida MM, Grüllich C, Weber TF, Herpel E, Bruckner T, Koschny R Abstract Recently, a tumor-autonomous cytochrome P450 (CYP)-3A5-mediated resistance to cancer therapy has been demonstrated in pancreatic ductal adenocarcinoma. Expression of CYP3A5, which is involved in the degradation of irinotecan, has also been reported in colorectal cancer (CRC). The aim of the present study was to analyze CYP3A5 expression in the normal colon, colon adenoma, CRC and normal tissues, as well as to examine whether CYP3A5 expression in CRC has an impact on tumor response to irinotecan treatment. Immuno...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
AbstractNonspecificity and high toxicity limit the treatment efficacy and safety of chemoradiation therapy. Effective tumor targeting of anticancer drugs and radiosensitizing agents is highly desirable to amplify the efficacy of this standard cancer therapy approach. To achieve this goal, we exploited the synergy of cisplatin and gold nanoparticles (AuNPs) co ‐loaded into alginate hydrogel network, forming so‐called ACA nanocomplex, and X‐ray radiation. Cisplatin is a commonly used anticancer agent, and at the same time, along with AuNPs could function as radiosensitizers to enhance the radiation‐induced damages th...
Source: Journal of Biomedical Materials Research Part B: Applied Biomaterials - Category: Materials Science Authors: Tags: Original Research Report Source Type: research
Abstract Nonspecificity and high toxicity limit the treatment efficacy and safety of chemoradiation therapy. Effective tumor targeting of anticancer drugs and radiosensitizing agents is highly desirable to amplify the efficacy of this standard cancer therapy approach. To achieve this goal, we exploited the synergy of cisplatin and gold nanoparticles (AuNPs) co-loaded into alginate hydrogel network, forming so-called ACA nanocomplex, and X-ray radiation. Cisplatin is a commonly used anticancer agent, and at the same time, along with AuNPs could function as radiosensitizers to enhance the radiation-induced damages t...
Source: Biomed Res - Category: Research Authors: Tags: J Biomed Mater Res B Appl Biomater Source Type: research
Publication date: Available online 6 March 2019Source: Reactive and Functional PolymersAuthor(s): Po-Chung Chen, Doris Yii, Hsieh-Chih Tsai, Vijaya Rohini Parasuraman, A.K. Prasannan, Chen-Yu Kao, Juin-Yih LaiAbstractSelf-assembly of nanoparticles (NP) with suitable sizes and surface charge to satisfy the functions of an efficient drug carrier plays a vital role in cancer therapy. Hence, the present study focused to prepare polymeric nanoparticles consisting of branched polyethylenimine (PEI), alginic acid (ALG) and poly(cyclohexane-1,4-diyl acetone dimethylene ketal) (PCADK), which were used to deliver an anticancer drug ...
Source: Reactive and Functional Polymers - Category: Chemistry Source Type: research
Background: Cost-utility analysis (CUA) is becoming more commonly used in healthcare decision-making. CUA uses the quality-adjusted life-years (QALY) metric, which combines the length of life with the health-related quality of life (HRQoL). Most QALY-measuring instruments were validated for general populations. For patients with cancer, the perception of their health state is different and may vary by the type of cancer considered. In Quebec, no preference weights for QALY have been developed, neither for the general population nor particular subpopulations. Methods/design: This survey is a prospective, longitudinal c...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research
Publication date: Available online 27 February 2019Source: International Journal of PharmaceuticsAuthor(s): Cenk Daglioglu, Fatma Necmiye KaciAbstractChemotherapy frequently involves combination treatment protocols to maximize tumor cell killing. Unfortunately these intensive chemotherapeutic regimes, often show disappointing results due to the development of drug resistance and higher nonspecific toxicity on normal tissues. In cancer treatment, it is critically important to minimize toxicity while preserving efficacy. We have previously addressed this issue and proposed a nanoparticle-based combination therapy involving b...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Colorectal Cancer | Nuclear Medicine